SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.23+0.21 (+5.22%)
Close on Oct 19, 2026
- Market cap
- $420.09M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.82 (−57.91%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ARS Pharmaceuticals, Inc. grew revenue 4.1% to $116.93M over the twelve months to Jun 30, 2026. Free cash flow was -$196.60M.
Revenue
$116.93M
+4.1% vs. a year earlier
Operating income
-$216.27M
TTM Q2 2026
Free cash flow
-$196.60M
TTM Q2 2026
EPS, diluted
-$2.18
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $420.09M
- P/E ratio
- –
- Price to sales
- 3.59
- Price to book
- 33.58
- Dividend yield
- –
- Free cash flow yield
- -46.80%
Fundamentals
- Revenue
- $116.93M
- Net income
- -$215.43M
- EPS, diluted
- -$2.18
- Free cash flow
- -$196.60M
- Book value per share
- $0.13
- Diluted shares
- 99M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$116.93M+4.1% YoY
Gross profit
–
Operating income
-$216.27M
Net income
-$215.43M
EPS, diluted
-$2.18
Free cash flow
-$196.60M
Reported periodTrailing twelve months